A six-month cohort study reported that RA patients positive for ACPA, RF, and anti-MAA IgG antibody were more than twice [95% CI: 1.57-3.51] as likely to achieve DAS28 improvement of >1.2 units and had an average 0.48 [95% CI: 0.26-0.70] units greater DAS28 improvement following treatment with biologic disease-modifying anti-rheumatic drugs (DMARDs), compared to RA patients negative for all three antibodies (34). This evidence concerns the gene PRTN3 and rheumatoid arthritis.